Device Trial Radar · NCT04911257
Interbody Systems: Post Market Clinical Follow-up Study
Last checked: Nov 19, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
28
Actual
Start
Dec 7, 2021
Primary completion
Feb 12, 2025
Study completion Mar 21, 2025
Sponsor
- Lead sponsor
- K2M, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 3, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing Stryker Interbody Systems that require post market clinical follow up (PMCF). The primary study hypothesis for each system is that the mean change in NDI (cervical) or ODI (lumbar) from baseline to Month 12 \< -10, that is, the mean improvement exceeds 10 points. In supporting analysis, the same hypotheses will be tested for mean change from baseline to 24 months to demonstrate durability of effectiveness.
Conditions
- Degenerative Disc Disease
Interventions
Cervical or Lumbar Spinal fusionDevice
This is a prospective, multi-center study of subjects who will undergo spinal fusion surgery utilizing certain Stryker Interbody Systems.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Oswestry Disability Index ChangeTime frame: 12 Months
- Mean Neck Disability Index ChangeTime frame: 12 Months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Spine Institute of Louisiana Foundation, Inc.
Shreveport, Louisiana
Cleveland Clinic
Cleveland, Ohio
The Spine Clinic of Oklahoma City
Oklahoma City, Oklahoma
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.